Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.
The anatomic response to intravitreal bevacizumab injection in three patients with aggressive, posterior retinopathy of prematurity is described. In all cases, the worse eye was treated with a single intravitreal injection of 0.75 mg of bevacizumab as monotherapy or complementary to laser therapy. In 24 hours, all injected eyes showed regression of the tunica vasculosa lentis and iris vessel engorgement and disappearance of iris rigidity. In addition, plus disease and retinal proliferation began to regress. None of the eyes required additional treatment. Follow-up of up to 10 months
Travassos
António
A
Pediatric Retina Department, Ophthalmology Service, Hospital Fernando Fonseca, Lisbon, Portugal.
Teixeira
Susana
S
Ferreira
Pinto
P
Regadas
Isaura
I
Travassos
Ana Sofia
AS
Esperancinha
Florindo Esteves
FE
Prieto
Isabel
I
Pires
Grapa
G
van Velze
Robert
R
Valido
A
A
Machado
Maria do Céu
Mdo C
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D007267:Injections; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab